Adrien DE VOEGHT

Dr. Adrien DE VOEGHT


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Blood
Verified
Journal Article
Open access
Naval DaverNaval Daver
Naval Daver
PVParesh Vyas
Paresh Vyas
GHGerwin Huls
Gerwin Huls
HDHartmut Döhner
Hartmut Döhner
SMSébastien Maury
Sébastien Maury
GMGuru Subramanian Guru Murthy
Guru Subramanian Guru Murthy
Patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC) have limited treatment options. The phase 3 ENHANCE-3 study aimed to determine whether magrolimab (magrolimab arm) was superior to placebo (control arm) when either was combined with venetoclax and azacitidine. Adults with previously untreated AML who were ineligible for IC were randomized to receive magrolimab (1 mg/kg on days 1 and 4, 15 mg/kg on day 8, 30 mg/kg on days 11 and 15, then weekly for 5 weeks, and then every 2 weeks) or placebo, venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter), and azacitidine (75 mg/m2 days 1-7) in 28-day cycles. The primary end point was overall survival (OS); key secondary end points included complete remission (CR) rate and safety. After randomization of 378 patients, the trial was stopped at a prespecified interim analysis owing to futility. At final analysis, with median follow-up of 7.6 months (magrolimab arm) vs 7.4 months (control arm), median OS was 10.7 vs 14.1 months (hazard ratio, 1.178; 95% confidence interval, 0.848-1.637). The CR rate within 6 cycles was 41.3% vs 46.0%. Addition of magrolimab to venetoclax and azacitidine resulted in more fatal adverse events (19.0% vs 11.4%), primarily driven by grade 5 infections (11.1% vs 6.5%) and respiratory events (2.6% vs 0%). There were similar incidences of any-grade infections, febrile neutropenia, and neutropenia between arms. These results highlight the difficulty in improving outcomes for patients with AML who were ineligible for IC. This trial was registered at www.clinicaltrials.gov as #NCT05079230.

27 March 2016 in AIDS
Verified
Journal Article
Closed access
AVAdrien DE VOEGHT
Adrien DE VOEGHT
NMNathalie Maes
Nathalie Maes
MMMichel Moutschen
Michel Moutschen
Objective: To compare microbial translocation and its biomarkers in HIV-1-infected African and White patients of the Liège AIDS Reference Center. Design: The study is based on a cross-sectional dataset of HIV-infected patients treated at the Liège AIDS Reference Center. Groups of white and African patients have been randomly selected to be identical for sex, age and duration of treatment. Methods: sCD14, lipopolysaccharide (LPS), lipopolysaccharide-binding protein (LBP) and routine HIV-follow-up parameters were measured on plasma samples. Results: High values of LPS and LBP were observed in both groups of patients without significant difference between them. High values of sCD14 were observed in 53.1% of whites and only in 18.8% of African patients (P = 0.0042). A correlation between LPS and sCD14 was observed in whites but not African patients. Conclusion: Our observation suggests that factors not related to microbial translocation are responsible for lower sCD14 value in Africans.

31 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AVAdrien DE VOEGHT
Adrien DE VOEGHT
EWEvelyne Willems
Evelyne Willems
SSSophie Servais
Sophie Servais
LSLaurence Seidel
Laurence Seidel
MPMichelle Pirotte
Michelle Pirotte
FBFrédéric Baron
Frédéric Baron
Background. Allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients requiring intensive care unit (ICU) have high mortality rates. Methods. In the current study, we retrospectively assessed whether the Prognostic Index for Critically Ill Allogeneic Transplantation patients (PICAT) score predicted overall survival in a cohort of 111 consecutive allo-HCT recipients requiring ICU. Results. Survival rates at 30 days and 1 year after ICU admission were 57.7% and 31.5%, respectively, and were significantly associated with PICAT scores (p = 0.036). Specifically, survival at 30-day for low, intermediate, and high PICAT scores was 64.1%, 58.1%, and 31.3%, respectively. At one-year, the figures were 37.5%, 29%, and 12.5%, respectively. In multivariate analyses, high PICAT score (HR = 2.23, p = 0.008) and relapse prior to ICU admission (HR = 2.98, p = 0.0001) predicted higher mortality. We next compared the ability of the PICAT and the Sequential Organ Failure Assessment (SOFA) scores to predict mortality in our patients using c-statistics. C statistics for the PICAT and the SOFA scores were 0.5687 and 0.6777, respectively. Conclusions. This study shows that while the PICAT score is associated with early and late mortality in allo-HCT recipients requiring ICU, it is outperformed by the SOFA score to predict their risk of mortality.

22 December 2024 in IDCases
Verified
Journal Article
Open access
SSSarah Sakalihasan
Sarah Sakalihasan
FLFrédéric Lifrange
Frédéric Lifrange
MCMathieu Czajkowski
Mathieu Czajkowski
VGVeronique Goncette
Veronique Goncette
BDBernard Duysinx
Bernard Duysinx
AVAdrien DE VOEGHT
Adrien DE VOEGHT
Bispecific antibody is a new treatment for hematological disease, especially for lymphoma, myeloma and acute lymphoblastic leukemia. This class of treatment presents the same kind of side effect as CAR-T cell which are immune-mediated. Nevertheless, infectious complication remains a major concerns with related mortality. Fungal infection are rarely reported in clinical trial but remains a major concern. We report a case of a co-infection of Aspergillus and Mucorales in a patient with diffuse large B-cell lymphoma (DLBCL) following treatment with the bispecific antibody epcoritamab. The patient developed severe cytokine release syndrome (CRS) and subsequent fungal infections, which were challenging to diagnose and treat due to the complexities of managing immunocompromised patients and co-infection. Advanced diagnostics, including PET-CT, and a combination of antifungal therapies were crucial in achieving remission. The case underscores the need for early diagnosis, multidisciplinary management, and innovative treatment strategies in similar high-risk patients.

22 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AVAdrien DE VOEGHT
Adrien DE VOEGHT
DCDoriane Calmes
Doriane Calmes
FBFloran Beck
Floran Beck
JSJean-Baptiste Sylvestre
Jean-Baptiste Sylvestre
PDPhilippe Delvenne
Philippe Delvenne
JCJean-Luc Canivet
Jean-Luc Canivet
Hypoxemia and coagulopathy are common in severe symptomatic patients of coronavirus disease 2019 (COVID-19). Histological evidence shows implication of complement activation and lung injury. We research sign of complement activation and presence of thrombotic microangiopathy in 8 severe patients. Six of them presented moderate elevation of final pathway of complement – sC5b-9 (median value : 350 ng/mL [IQR : 300,5 - 514,95 ng/mL]). Two patients have been autopsied and presence of thrombotic microvascular injury have been found. Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000). Finally, all 8 patients had elevated d-dimer (median value : 2226 µgr/l [IQR : 1493 – 2362]) and soluble fibrin monomer complex (median value : 8.5 mg/mL, IQR[<6 – 10.6]). In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy. Key points: Severe covid-19 patients show moderate elevation of final activation of complement No sign of Thrombotic microangiopathy is found in severe covid-19 patients

1 January 2013
Verified
Journal Article
Closed access
BPB F Pirotte
B F Pirotte
MRM Rassenfosse
M Rassenfosse
RCR Collin
R Collin
AVAdrien DE VOEGHT
Adrien DE VOEGHT
MMM Moutschen
M Moutschen
ECE Cavalier
E Cavalier